A Phase II Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2017
At a glance
- Drugs TG 4010 (Primary) ; Nivolumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Transgene
- 20 Nov 2017 Status changed from planning to not yet recruiting.
- 11 Sep 2017 According to a Transgene media release, US FDA granted Investigational New Drug (IND) clearance to proceed with this trial and first patient is expected to be included into this Phase 2 study at the end of 2017.
- 26 Apr 2017 New trial record